Unlock a deeper understanding of today’s most advanced cancer treatments with this two‑part course led by Dr Elaine Vickers – one of the UK’s foremost independent educators in the science of modern cancer therapies who will guide you through many of the most relevant topics relating to modern systemic treatments for non-small cell lung cancer (NSCLC).
In the first session, Elain will focus on the gene faults that drive many NSCLCs and on the targeted treatments that exploit these faults, such as inhibitors of EGFR, ALK, ROS1, B-Raf, HER2, MET, and RET.
The second session explores cancer’s relationship with the immune system and focuses on the checkpoint inhibitor group of immunotherapies, which include PD-1, PD-L1 and CTLA-4 targeted antibody therapies.
Dr Vickers’ goal is to explain the science that underpins each treatment. She also hopes to provide learners with a broad understanding of why treatments work well for some patients but not for others.
To read more and register click here.